Stuart A. Tross Sells 55,000 Shares of MannKind Co. (NASDAQ:MNKD) Stock

MannKind Co. (NASDAQ:MNKD - Get Free Report) insider Stuart A. Tross sold 55,000 shares of the business's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $7.34, for a total transaction of $403,700.00. Following the transaction, the insider now directly owns 967,191 shares in the company, valued at $7,099,181.94. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

MannKind Stock Down 0.6 %

Shares of MNKD traded down $0.04 during mid-day trading on Friday, hitting $7.35. 4,822,462 shares of the company's stock were exchanged, compared to its average volume of 2,065,039. The firm has a fifty day moving average of $6.52 and a two-hundred day moving average of $5.54. MannKind Co. has a twelve month low of $3.17 and a twelve month high of $7.63. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of 183.67 and a beta of 1.30.

MannKind (NASDAQ:MNKD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.01 by $0.04. MannKind had a net margin of 4.73% and a negative return on equity of 11.97%. The company had revenue of $72.39 million for the quarter, compared to analyst estimates of $64.81 million. During the same quarter in the prior year, the business posted ($0.02) EPS. MannKind's quarterly revenue was up 48.9% on a year-over-year basis. On average, equities analysts predict that MannKind Co. will post 0.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MNKD. Mirae Asset Global Investments Co. Ltd. grew its stake in MannKind by 5.7% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 186,532 shares of the biopharmaceutical company's stock valued at $845,000 after buying an additional 9,998 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in MannKind in the 1st quarter valued at $450,000. ProShare Advisors LLC boosted its holdings in MannKind by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 65,811 shares of the biopharmaceutical company's stock valued at $298,000 after purchasing an additional 5,416 shares during the period. EntryPoint Capital LLC boosted its holdings in MannKind by 60.9% in the 1st quarter. EntryPoint Capital LLC now owns 23,809 shares of the biopharmaceutical company's stock valued at $108,000 after purchasing an additional 9,008 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in MannKind by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 172,054 shares of the biopharmaceutical company's stock valued at $780,000 after purchasing an additional 9,410 shares during the period. Institutional investors and hedge funds own 49.55% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Oppenheimer boosted their price objective on shares of MannKind from $10.00 to $12.00 and gave the company an "outperform" rating in a research report on Wednesday, August 28th. Leerink Partnrs raised shares of MannKind to a "strong-buy" rating in a research report on Monday, September 9th. Finally, Leerink Partners assumed coverage on shares of MannKind in a research report on Monday, September 9th. They set an "outperform" rating and a $8.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $8.67.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.